Clinical Trial Update: A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessed the safety of GRF6019 infusions in subjects with severe Alzheimer's disease; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GRF6019

Snippet

Sponsor: Alkahest, Inc. | Conditions: Severe Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-01-27